BNP Paribas Financial Markets
BBIO icon

BNP Paribas Financial Markets’s BridgeBio Pharma BBIO Stock Holding History

BNP Paribas Financial Markets’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.1M Sell
1,155,442
-151,734
-12% -$10.6M 0.03% 512
2026
Q1 		$97.1M Sell
1,307,176
-285,484
-18% -$20.7M 0.05% 421
2025
Q4 		$122M Buy
1,592,660
+953,396
+149% +$62.6M 0.06% 341
2025
Q3 		$33.2M Buy
639,264
+200,198
+46% +$9.76M 0.02% 820
2025
Q2 		$19M Buy
439,066
+124,364
+40% +$4.52M 0.01% 1070
2025
Q1 		$10.9M Buy
314,702
+289,492
+1,148% +$9.76M 0.01% 1363
2024
Q4 		$692K Sell
25,210
-12,829
-34% -$332K ﹤0.01% 3071
2024
Q3 		$968K Buy
38,039
+24,738
+186% +$649K ﹤0.01% 2518
2024
Q2 		$337K Sell
13,301
-124,643
-90% -$3.41M ﹤0.01% 2855
2024
Q1 		$4.27M Buy
137,944
+10,684
+8% +$363K ﹤0.01% 1567
2023
Q4 		$5.14M Sell
127,260
-21,632
-15% -$650K 0.01% 1384
2023
Q3 		$3.93M Buy
148,892
+41,840
+39% +$1.19M 0.01% 1441
2023
Q2 		$1.84M Sell
107,052
-7,294
-6% -$110K ﹤0.01% 1803
2023
Q1 		$1.9M Sell
114,346
-20,158
-15% -$235K ﹤0.01% 1855
2022
Q4 		$1.02M Buy
+134,504
New +$1.29M ﹤0.01% 2148
2022
Q3 		– Sell
-129,984
Closed -$1.18M – 4748
2022
Q2 		$1.18M Sell
129,984
-116,964
-47% -$978K ﹤0.01% 2099
2022
Q1 		$2.51M Buy
246,948
+220,646
+839% +$2.26M ﹤0.01% 1677
2021
Q4 		$439K Buy
26,302
+3,320
+14% +$140K ﹤0.01% 3069
2021
Q3 		$1.08M Buy
22,982
+16,641
+262% +$892K ﹤0.01% 2326
2021
Q2 		$387K Sell
6,341
-8,141
-56% -$465K ﹤0.01% 2655
2021
Q1 		$892K Buy
14,482
+3,303
+30% +$216K ﹤0.01% 2211
2020
Q4 		$795K Sell
11,179
-5,956
-35% -$287K ﹤0.01% 2178
2020
Q3 		$643K Buy
17,135
+8,458
+97% +$266K ﹤0.01% 2065
2020
Q2 		$283K Sell
8,677
-17,037
-66% -$519K ﹤0.01% 2351
2020
Q1 		$746K Buy
25,714
+22,467
+692% +$697K ﹤0.01% 2118
2019
Q4 		$114K Sell
3,247
-51
-2% -$1.41K ﹤0.01% 3233
2019
Q3 		$70.8K Buy
+3,298
New +$91.2K ﹤0.01% 3306

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

BNP Paribas Financial Markets's BBIO Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its BridgeBio Pharma (BBIO) stake by 12% in Q2 2026, selling an estimated $10.6M and leaving 1,155,442 shares worth $86.1M. The position accounts for 0.03% of the portfolio, ranked #512.

BNP Paribas Financial Markets first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. The position peaked at $122M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • BNP Paribas Financial Markets held 1,155,442 shares of BridgeBio Pharma worth $86.1M as of Q2 2026.
  • BNP Paribas Financial Markets sold 151,734 BridgeBio Pharma shares in Q2 2026, an estimated $10.6M.
  • BridgeBio Pharma made up 0.03% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #512 holding.
  • BNP Paribas Financial Markets first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • BNP Paribas Financial Markets's BridgeBio Pharma position peaked at $122M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.